David E. Cohn

Obstetrics and Gynecology
3651 Ridge Mill Dr
Hilliard, OH 43026

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 264 publications

Correction: Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.

Correction: Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.

Journal: Oncogene
Published: August 03, 2026

Prognostic value of the nutritional risk index and prognostic nutritional index for immunotherapy outcomes in cervical Cancer.

Prognostic value of the nutritional risk index and prognostic nutritional index for immunotherapy outcomes in cervical Cancer.

Journal: Gynecologic oncology reports
Published: June 14, 2026

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Journal: Gynecologic oncology
Published: June 12, 2026

Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer.

Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer.

Journal: Gynecologic oncology
Published: May 29, 2026

Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?

Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?

Journal: Gynecologic oncology
Published: April 14, 2026

Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma.

Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma.

Journal: Gynecologic oncology
Published: April 07, 2026

No time to waste: Evaluation of diagnostic delays in vulvar cancer.

No time to waste: Evaluation of diagnostic delays in vulvar cancer.

Journal: Gynecologic oncology
Published: April 05, 2026

Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma.

Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma.

Journal: Cells
Published: March 16, 2026

Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study.

Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study.

Journal: Gynecologic oncology
Published: February 23, 2026

Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer.

Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer.

Journal: Gynecologic oncology
Published: January 19, 2026

Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma.

Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma.

Journal: Gynecologic oncology reports
Published: May 14, 2025

The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.

The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.

Journal: Gynecologic oncology
Published: May 06, 2025
Showing 1-12 of 264

Last Updated: 09/26/2026